CA2706914A1 - Biocompatible biodegradable fumagillin analog conjugates - Google Patents
Biocompatible biodegradable fumagillin analog conjugates Download PDFInfo
- Publication number
- CA2706914A1 CA2706914A1 CA2706914A CA2706914A CA2706914A1 CA 2706914 A1 CA2706914 A1 CA 2706914A1 CA 2706914 A CA2706914 A CA 2706914A CA 2706914 A CA2706914 A CA 2706914A CA 2706914 A1 CA2706914 A1 CA 2706914A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- conjugate
- fumagillin
- optionally substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US458207P | 2007-11-28 | 2007-11-28 | |
| US61/004,582 | 2007-11-28 | ||
| PCT/US2008/084539 WO2009073445A2 (en) | 2007-11-28 | 2008-11-24 | Biocompatible biodegradable fumagillin analog conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2706914A1 true CA2706914A1 (en) | 2009-06-11 |
Family
ID=40600044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2706914A Abandoned CA2706914A1 (en) | 2007-11-28 | 2008-11-24 | Biocompatible biodegradable fumagillin analog conjugates |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8399512B2 (https=) |
| EP (1) | EP2217283A2 (https=) |
| JP (1) | JP5557746B2 (https=) |
| CN (1) | CN101990441A (https=) |
| AU (1) | AU2008331516B2 (https=) |
| BR (1) | BRPI0820229A2 (https=) |
| CA (1) | CA2706914A1 (https=) |
| EA (1) | EA020251B1 (https=) |
| IL (1) | IL206057A0 (https=) |
| MX (1) | MX2010005857A (https=) |
| NZ (2) | NZ600039A (https=) |
| WO (1) | WO2009073445A2 (https=) |
| ZA (1) | ZA201003819B (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE507845T1 (de) | 2003-09-05 | 2011-05-15 | Gen Hospital Corp | Polyacetal-arzneimittelkonjugate als freisetzungssystem |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| CA2731020A1 (en) * | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| AR074584A1 (es) * | 2008-12-10 | 2011-01-26 | Mersana Therapeutics Inc | Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables |
| AU2010254013A1 (en) * | 2009-05-28 | 2011-11-24 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| MX337575B (es) | 2009-10-09 | 2016-03-10 | Zafgen Corp | Compuestos de sulfona y métodos para lafabricación y uso de éstos. |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| JP5827239B2 (ja) | 2010-01-08 | 2015-12-02 | ザフゲン，インコーポレイテッド | フマギロール型化合物並びにその製造方法及び使用方法 |
| EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| US9895449B2 (en) * | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| AU2011281037B2 (en) | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| AU2011336785A1 (en) | 2010-11-29 | 2013-06-20 | Zafgen, Inc | Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
| KR101875988B1 (ko) | 2011-03-08 | 2018-07-06 | 자프겐 인크. | 옥사스피로[2.5]옥탄 유도체 및 유사체 |
| US9242997B2 (en) | 2011-05-06 | 2016-01-26 | Zafgen, Inc. | Tricyclic pyrazole sulphonamide compunds and methods of making and using same |
| CN103748094B (zh) | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | 三环磺酰胺化合物及其制备和使用方法 |
| SG194812A1 (en) | 2011-05-06 | 2013-12-30 | Zafgen Inc | Partially saturated tricyclic compounds and methods of making and using same |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
| UY34542A (es) * | 2011-12-23 | 2013-07-31 | Mersana Therapeutics Inc | ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. |
| WO2013109735A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| WO2013169727A1 (en) | 2012-05-07 | 2013-11-14 | Zafgen, Inc. | Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same |
| EP2846792B1 (en) | 2012-05-08 | 2018-08-15 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| WO2013169860A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
| BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
| MX2015005733A (es) | 2012-11-05 | 2016-02-10 | Zafgen Inc | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
| KR20150079952A (ko) | 2012-11-05 | 2015-07-08 | 자프겐 인크. | 트리시클릭 화합물 및 그의 제조 및 사용 방법 |
| US9597309B2 (en) | 2013-03-14 | 2017-03-21 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
| CA2908993C (en) | 2013-04-10 | 2023-05-23 | Syndevrx, Inc. | Metap2 inhibitors and methods of treating obesity |
| ES2754397T3 (es) | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| JP6493868B2 (ja) * | 2014-09-24 | 2019-04-03 | 日東電工株式会社 | ジグリコールアミド酸型配位子を有するビニルモノマー |
| AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| CN113209306A (zh) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
| CN111620861A (zh) | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3239447A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| RU2018147224A (ru) | 2016-06-08 | 2020-07-14 | Эббви Инк. | Конъюгаты антитела к egfr и лекарственного средства |
| WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| BR112018075639A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| CA3033646A1 (en) * | 2016-08-11 | 2018-02-15 | Zafgen, Inc. | Fumagillol compounds and methods of making and using same |
| CN110177805B (zh) | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| AU2017383142A1 (en) | 2016-12-22 | 2019-07-04 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43 |
| CN106831662B (zh) * | 2016-12-29 | 2018-12-18 | 中国农业科学院蜜蜂研究所 | 一种胺基多元醇代烟曲霉素及其合成方法与应用 |
| AU2018290330A1 (en) | 2017-06-22 | 2020-01-02 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| WO2019118612A1 (en) * | 2017-12-12 | 2019-06-20 | Zafgen, Inc. | Targeting compounds |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| CN120795120A (zh) | 2018-06-05 | 2025-10-17 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| JP2022512826A (ja) | 2018-10-26 | 2022-02-07 | シンデブルックス，インコーポレイティド | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| US12037378B2 (en) | 2019-05-21 | 2024-07-16 | Novartis Ag | Variant CD58 domains and uses thereof |
| BR112022002067A2 (pt) | 2019-08-08 | 2022-06-14 | Regeneron Pharma | Formatos de molécula de ligação ao antígeno |
| MX2022005330A (es) | 2019-11-05 | 2022-05-26 | Regeneron Pharma | Moleculas de union multiespecificas con scfv en el extremo nterminal. |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| JP2023516080A (ja) | 2020-03-06 | 2023-04-17 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
| US20230128499A1 (en) | 2020-03-27 | 2023-04-27 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune diseases |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| US20250101126A1 (en) | 2021-08-05 | 2025-03-27 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| EP4396232A1 (en) | 2021-09-03 | 2024-07-10 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| CN118354789A (zh) | 2021-09-03 | 2024-07-16 | Go医疗股份有限公司 | 抗糖-cMET抗体及其用途 |
| IL314677A (en) * | 2022-02-16 | 2024-10-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Metap2 inhibitors and uses thereof |
| KR20250148746A (ko) | 2023-01-13 | 2025-10-14 | 리제너론 파아마슈티컬스, 인크. | Fgfr3 결합 분자 및 그의 사용 방법 |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) * | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| US5164410A (en) * | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| JP2858724B2 (ja) * | 1988-09-01 | 1999-02-17 | 武田薬品工業株式会社 | 血管新生阻害剤 |
| US5180738A (en) * | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| EP0682020A1 (en) * | 1988-09-01 | 1995-11-15 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives useful as angiogenesis inhibitors |
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) * | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| EP0602586B1 (en) * | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| UA41446C2 (uk) * | 1995-03-27 | 2001-09-17 | Санофі - Сінтелабо | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі |
| US5811510A (en) * | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| US6207704B1 (en) * | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| WO1999061432A1 (en) | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
| KR100357541B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| US6603812B1 (en) * | 1998-08-17 | 2003-08-05 | Linear Technology Corporation | Hardware implementation of a decimating finite impulse response filter |
| AU6409499A (en) * | 1998-10-01 | 2000-04-17 | Children's Medical Center Corporation | Method of treatment of cardiovascular injuries |
| PT1156829E (pt) * | 1999-02-26 | 2007-08-17 | Sanofi Aventis | ''formulação estável contendo fumagilina'' |
| HUP9901943A2 (hu) * | 1999-06-11 | 2001-12-28 | Sanofi-Synthelabo | Eljárás fumagillin előállítására |
| US7160924B2 (en) * | 2002-07-19 | 2007-01-09 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6822086B1 (en) * | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| GB0012179D0 (en) * | 2000-05-20 | 2000-07-12 | Imp Cancer Res Tech | Assays and drug screening systems |
| US6919307B2 (en) * | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6548477B1 (en) * | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| AU3947902A (en) * | 2000-11-01 | 2002-06-03 | Praecis Pharm Inc | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7105482B2 (en) * | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| DE60233420D1 (de) * | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US6803382B2 (en) * | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
| WO2003070823A2 (en) * | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| EP1494662B1 (en) * | 2002-04-11 | 2012-11-28 | Children's Medical Center Corporation | Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof |
| EP1534269B1 (en) * | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
| ATE507845T1 (de) * | 2003-09-05 | 2011-05-15 | Gen Hospital Corp | Polyacetal-arzneimittelkonjugate als freisetzungssystem |
| FR2872511B1 (fr) * | 2004-06-30 | 2006-08-11 | Galderma Res & Dev | Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique |
| EP1888121A2 (en) * | 2005-05-12 | 2008-02-20 | Tapestry Pharmaceuticals, Inc. | Anticancer targeted conjugates comprising a succinyl or glutaryl linker |
| ES2457418T3 (es) * | 2007-07-16 | 2014-04-25 | Abbvie Inc. | Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas |
| BRPI0820229A2 (pt) | 2007-11-28 | 2017-05-09 | A Stevenson Cheri | conjugados de análogos de fumagilina biodegradáveis biocompatíveis |
| AU2010254013A1 (en) * | 2009-05-28 | 2011-11-24 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
-
2008
- 2008-11-24 BR BRPI0820229A patent/BRPI0820229A2/pt not_active IP Right Cessation
- 2008-11-24 NZ NZ600039A patent/NZ600039A/xx not_active IP Right Cessation
- 2008-11-24 US US12/276,856 patent/US8399512B2/en not_active Expired - Fee Related
- 2008-11-24 NZ NZ585547A patent/NZ585547A/xx not_active IP Right Cessation
- 2008-11-24 JP JP2010536101A patent/JP5557746B2/ja not_active Expired - Fee Related
- 2008-11-24 CN CN2008801221269A patent/CN101990441A/zh active Pending
- 2008-11-24 CA CA2706914A patent/CA2706914A1/en not_active Abandoned
- 2008-11-24 MX MX2010005857A patent/MX2010005857A/es active IP Right Grant
- 2008-11-24 AU AU2008331516A patent/AU2008331516B2/en not_active Ceased
- 2008-11-24 EA EA201070657A patent/EA020251B1/ru not_active IP Right Cessation
- 2008-11-24 WO PCT/US2008/084539 patent/WO2009073445A2/en not_active Ceased
- 2008-11-24 EP EP08857683A patent/EP2217283A2/en not_active Withdrawn
-
2010
- 2010-05-27 ZA ZA2010/03819A patent/ZA201003819B/en unknown
- 2010-05-27 IL IL206057A patent/IL206057A0/en unknown
-
2013
- 2013-02-15 US US13/769,024 patent/US20130158046A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010005857A (es) | 2010-11-22 |
| WO2009073445A3 (en) | 2010-01-28 |
| BRPI0820229A2 (pt) | 2017-05-09 |
| ZA201003819B (en) | 2013-09-25 |
| IL206057A0 (en) | 2010-11-30 |
| CN101990441A (zh) | 2011-03-23 |
| US20130158046A1 (en) | 2013-06-20 |
| EA020251B1 (ru) | 2014-09-30 |
| US20090148396A1 (en) | 2009-06-11 |
| AU2008331516A1 (en) | 2009-06-11 |
| EA201070657A1 (ru) | 2010-12-30 |
| JP5557746B2 (ja) | 2014-07-23 |
| EP2217283A2 (en) | 2010-08-18 |
| JP2011504964A (ja) | 2011-02-17 |
| NZ600039A (en) | 2013-11-29 |
| AU2008331516B2 (en) | 2014-01-09 |
| WO2009073445A2 (en) | 2009-06-11 |
| US8399512B2 (en) | 2013-03-19 |
| NZ585547A (en) | 2012-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008331516B2 (en) | Biocompatible biodegradable fumagillin analog conjugates | |
| EP2435053B1 (en) | Polyal drug conjugates comprising variable rate-releasing linkers | |
| AU2007267535B2 (en) | Aziridinyl-epothilone compounds | |
| CA2695297C (en) | Substituted cc-1065 analogs and their conjugates | |
| CA2657276A1 (en) | Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same | |
| JP2023119064A (ja) | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート | |
| CN103641925B (zh) | 水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途 | |
| KR20090024166A (ko) | 치료학적, 농업적 및 식품 첨가제 화합물의 폴리머 콘주게이트의 제조 | |
| EP2914600A2 (en) | Functionalized 9-bromo-camptothecin derivatives | |
| CN109153639B (zh) | 葫芦巴碱类化合物 | |
| CN100569740C (zh) | N-or酰胺类化合物,其制备方法和其应用 | |
| US10266547B2 (en) | Thieno[2,3-e]indole derivatives as new antitumor agents | |
| CN115784972A (zh) | 乙二胺衍生物及其制备方法与应用 | |
| KR20260028651A (ko) | 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
| WO2026036128A1 (en) | Compounds and methods for iron-dependent drug release | |
| TW202325273A (zh) | 靶向fap之中子捕獲劑及與其相關之用途及調配物 | |
| TW202521547A (zh) | 胜肽藥物複合體及其用途 | |
| HK1124335B (en) | Aziridinyl-epothilone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131122 |
|
| FZDE | Discontinued |
Effective date: 20160411 |